PureTech creates immuno-oncology firm | Chemical & Engineering News
Volume 95 Issue 16 | p. 13 | Concentrates
Issue Date: April 17, 2017

PureTech creates immuno-oncology firm

Department: Business
Keywords: start-ups, immuno-oncology, monoclonal antibodies

PureTech Health, an R&D and venture investment firm, has launched an immuno-oncology subsidiary called Nybo Therapeutics. Building on the work of NYU School of Medicine’s George Miller, Nybo will develop monoclonal antibodies to target and neutralize newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumors. The launch coincides with the publication of Miller’s research on the activation of the Dectin 1 immune receptor on macrophages (Nat. Med., 2017, DOI: 10.1038/nm.4314).

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment